In contrast to SMARCA4-proficient ovarian controls, SCCOHT and ER+ breast cancer cell lines retain RB and express lower levels of the CDK4/6 inhibitor p16INK4a (Fig. 3a), a profile that has been associated with positive responses to palbociclib15–19,33–35. Here, RB1 is linked to breast cancer.